Pre-Sale Begins Today for Amnion-Derived Drops to Comfort Dry Eyes
New biologic products from Regenerative Science – Genesis 2.0, ACE and Renaissance – contain mixture of more than 120 cytokines, proteins, and growth factors.
MANHATTAN BEACH, Calif. (July 9, 2019) – In August, Regenerative Science™, an affiliate of biotech company Ocular Science®, will debut three amnion-derived drops for dry eye disease. Pre-orders begin this week for the biologic drops – Genesis 2.0™, ACE™ and Renaissance™, which have the potential to help heal the ocular surfaces of the more than 30 million DED sufferers in the U.S. According to Ocular Science founder and CEO Anthony Sampietro, these products will provide patients with innovative alternatives to traditional synthetic medications and the more intrusive biologic treatments currently on the market.
“Our unique amniotic portfolio of biologics for managing dry eye separates Regenerative Science from the competition, and we want to provide physicians with this emerging treatment as soon as possible,” said Mr. Sampietro. “We are experiencing a strong demand for Genesis 2.0, ACE and Renaissance, which is why we are beginning pre-orders now.”
Designed to treat varying levels of dry eye disease, Genesis 2.0 (severe dry eye), ACE (moderate) and Renaissance (mild), which are derived from amnion and possess different concentrations of cytokines, growth factors and proteins, have the potential to decrease inflammation and facilitate corneal healing. Each product also offers a unique method of storage – Genesis 2.0 stores frozen, ACE stores refrigerated and Renaissance stores at room temperature.
“I expect Genesis 2.0, ACE and Renaissance to be very beneficial to my dry eye practice, particularly among my patients who can’t get the relief they need from commercially available products,” said Dr. Ken Beckman, MD, director of corneal services at Comprehensive Eyecare of Central Ohio and clinical assistant professor at The Ohio State University. “Evidence supports the use of amnion for treating dry eye disease, and I’ve had a lot of success with it in my practice.”
Mr. Sampietro noted that the three products represent “next-generation” versions of the company’s original biologic product, Genesis, a cryopreserved drop that launched in 2017 and was recently the subject of a study in Clinical Ophthalmology.
Regenerative Science’s biologics, which are regulated under section 361 of the Public Health Service Act, are formulated in a state-of-the-art tissue bank. The facility is registered with the Food and Drug Administration (FDA) and adheres to Current Good Manufacturing Practices (cGMP).
Mr. Sampietro added that his company has a special offer for those who pre-order. “For every five boxes of Genesis 2.0 purchased, we will add one box of ACE and Renaissance at no cost. Early purchasers will also be prioritized to receive product when our drops become commercially available in August.”
Here’s how medical providers (MDs and ODs only) can place pre-sale orders online:
- All pre-orders must be made placed at regenerativescience.com.
- Orders must be completed by and shipped to a licensed MD or OD’s office.
- First-time purchasers must complete an account form and, once vetted and approved, will be emailed an account number.
- Once an account number is received, it can be used to login into Regenerative Science’s ordering and purchasing platform as an existing account.
- Orders require a minimum of five boxes (per product) and must be shipped directly to the licensed medical provider’s office.
- All Regenerative Science products are cash-pay and not eligible for reimbursement through insurance.
ABOUT REGENERATIVE SCIENCE
Regenerative ScienceTM, an affiliate of biotech company Ocular Science® based in Manhattan Beach, Calif., innovates novel biologic eye drops for the treatment of dry eye disease. Its products – Genesis 2.0, ACE and Renaissance – are derived from amnion and each contain anti-inflammatory molecules, cytokines, proteins and growth factors to help reduce inflammation and provide advanced soothing relief. Regenerative Science products are formulated in a state-of-the-art tissue bank, which adheres to section 361 of the Public Health Service Act as well as the Current Good Manufacturing Practices (cGMP) set forth by the Food and Drug Administration (FDA). Learn more at regenerativescience.com.